Heart Attack News and Research

RSS

St. Jude Medical applauds the updated level of evidence for FFR-guided treatment

St. Jude Medical, Inc. applauds the updated level of evidence for Fractional Flow Reserve (FFR)-guided treatment in the Guidelines on Percutaneous Coronary Intervention (PCI).

17 Dec 2009

Deaths from heart disease peak in December and January, US database reveals

'Tis the season… for a heart attack? According to Dr. Keith Churchwell, associate director of the Vanderbilt Heart and Vascular Institute at Vanderbilt University Medical Center, a US database of 53 million deaths occurring between 1973 and 2001 reveals that deaths from heart disease peak in December and January, with spikes on Christmas and New Year's Day.

16 Dec 2009

Low plasma CETP activity associated with increased risk of heart disease, says study

Although seen as a potential heart disease therapy, raising high-density lipoprotein (HDL) cholesterol levels by inhibiting activity of a transfer protein may not be effective, a new study suggests.

16 Dec 2009

Intensive medical therapy may benefit patients with asymptomatic plaque buildup

Intensive medical therapy, including aggressive control of blood pressure and cholesterol levels, for patients with asymptomatic plaque buildup in their carotid arteries (which supply blood to the brain) appears to be associated with reduced rates of cardiovascular events and reduced risk of microemboli (microscopic-sized blood clots) in the brain arteries, according to a report posted online today that will appear in the February 2010 print issue of Archives of Neurology, one of the JAMA/Archives journals.

15 Dec 2009

Celebrex stops aspirin from doing its job effectively

Millions of Americans take Celebrex for arthritis or other pain. Many, if they are middle-aged or older, also take a low-dose aspirin tablet daily to reduce the risk of heart attack and stroke. Yet they may be getting little protection, because Celebrex keeps the aspirin from doing its job effectively, a new study suggests.

15 Dec 2009

Postmenopausal women who take antidepressants face increased risk for stroke and death

Postmenopausal women who take antidepressants face a small but statistically significant increased risk for stroke and death compared with those who do not take the drugs. The new findings are from the federally-funded, multi-institution, Women's Health Initiative Study sponsored by the National Institutes of Health, and the results are published in the December 14 online edition of Archives of Internal Medicine.

14 Dec 2009

Heart attacks peak during winter months, finds research

Research has found that heart attacks peak during the winter months, and the prevailing hypothesis has been that cold temperatures stress the heart. But in 2004, researchers analyzed 12 years of Los Angeles County death certificates and found that heart attack deaths also rise in the balmy Los Angeles winters.

14 Dec 2009

Patients with elevated CRP and normal LDL levels may benefit from statin therapy

New research shows a long-term benefit in screening people for CRP, a marker for inflammation, even if they have normal levels of bad cholesterol, because of increased long-term risk for heart attack, stroke and death.

14 Dec 2009

Special issue focuses on cardiovascular disease prevention and outcomes

Emerging research on cardiovascular risk factors and treatment effects are helping clinicians gain a better understanding of which patients are most likely to benefit from close monitoring, lifestyle changes and/or additional therapeutic interventions.

14 Dec 2009

HSMR helps identify sepsis as an area of concern for Canadian hospitals

A new study shows that in 2008-2009 more than 9,300 patients died of sepsis, a condition resulting from the body's response to severe infection, in Canadian hospitals outside Quebec.

11 Dec 2009

Latest findings on how blood clots form can open door to the development of new drugs

The latest findings on how blood clots form could open the door to the development of new and better-targeted drugs for patients at risk of strokes or heart attacks.

11 Dec 2009

Cardiac myosin-binding protein C identified as potential new diagnostic biomarker for heart attacks

Though they remain a leading killer, heart attacks can be effectively treated provided they can be rapidly diagnosed following initial onset of symptoms. In a study appearing in this month's Molecular and Cellular Proteomics, researchers have identified cardiac myosin-binding protein C (cMyBP-C) as a potential new diagnostic biomarker for heart attacks, one that may be particularly valuable for mild attacks in which traditional diagnostic proteins may not be abundant enough.

11 Dec 2009

Embryonic signalling pathways suggest a new therapeutic approach to recover from heart attack

Almost a century after it was discovered in fruit flies with notches in their wings, the Notch signalling pathway may come to play an important role in the recovery from heart attacks. In a study published today in Circulation Research, scientists at the European Molecular Biology Laboratory (EMBL) in Monterotondo, Italy, are the first to prove that this signalling pathway targets heart muscle cells and thus reveal its crucial role in heart development and repair

10 Dec 2009

New health study reveals Ontario women less likely to receive cardiac care than men

Gender differences persist in the quality of cardiac care across Ontario, according to a health study by researchers at St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES).

10 Dec 2009

Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated

Attached is a press release issued earlier this morning by GlaxoSmithKline, announcing that GSK has initiated its second pivotal Phase 3 trial to evaluate the efficacy of long-term treatment with the investigational Lp-PLA2 inhibitor darapladib in men and women with acute coronary syndrome (ACS).

10 Dec 2009

RegeneRx Biopharmaceuticals completes Phase I trial evaluating systemic administration of RGN-352

REGENERX BIOPHARMACEUTICALS, INC. announced today that it has completed and analyzed the safety data from its double-blind, placebo controlled Phase I clinical trial evaluating the systemic administration of RGN-352. The trial included testing of a single escalating intravenous dose of the drug candidate on forty healthy volunteers in Phase IA and, subsequently, over a fourteen-day treatment period on forty volunteers in Phase IB.

9 Dec 2009

Heart Attack News and Research

St. Jude Medical applauds the updated level of evidence for FFR-guided treatment

Deaths from heart disease peak in December and January, US database reveals

Low plasma CETP activity associated with increased risk of heart disease, says study

Intensive medical therapy may benefit patients with asymptomatic plaque buildup

Celebrex stops aspirin from doing its job effectively

Postmenopausal women who take antidepressants face increased risk for stroke and death

Heart attacks peak during winter months, finds research

Patients with elevated CRP and normal LDL levels may benefit from statin therapy

Special issue focuses on cardiovascular disease prevention and outcomes

HSMR helps identify sepsis as an area of concern for Canadian hospitals

Latest findings on how blood clots form can open door to the development of new drugs

Cardiac myosin-binding protein C identified as potential new diagnostic biomarker for heart attacks

Embryonic signalling pathways suggest a new therapeutic approach to recover from heart attack

New health study reveals Ontario women less likely to receive cardiac care than men

Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated

RegeneRx Biopharmaceuticals completes Phase I trial evaluating systemic administration of RGN-352

Experts call on Europe's policy makers to take urgent action against preventable strokes

New regenerative therapies for heart disease being developed

New IME-developed cardiac biomarker testing system saves time

University of Texas launches phase II clinical trial to test stem-cell-based therapy on injured heart muscle

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News